147 related articles for article (PubMed ID: 35873390)
1. Serum human chorionic gonadotropin ratios for the detection of etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine resistance in high-risk gestational trophoblastic neoplasia.
Sirimusika N; Boonyapipat S
Health Sci Rep; 2022 Jul; 5(4):e729. PubMed ID: 35873390
[TBL] [Abstract][Full Text] [Related]
2. Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia.
Rattanaburi A; Boonyapipat S; Supasinth Y
Asian Pac J Cancer Prev; 2015; 16(12):5037-41. PubMed ID: 26163637
[TBL] [Abstract][Full Text] [Related]
3. Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.
Lybol C; Westerdijk K; Sweep FCGJ; Ottevanger PB; Massuger LFAG; Thomas CMG
Ann Oncol; 2012 Nov; 23(11):2903-2906. PubMed ID: 22730100
[TBL] [Abstract][Full Text] [Related]
4. M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first-line treatment of high-risk gestational trophoblastic neoplasia.
Singh K; Gillett S; Ireson J; Hills A; Tidy JA; Coleman RE; Hancock BW; Winter MC
Int J Cancer; 2021 May; 148(9):2335-2344. PubMed ID: 33210289
[TBL] [Abstract][Full Text] [Related]
5. Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy.
Cortés-Charry R; Hennah L; Froeling FEM; Short D; Aguiar X; Tin T; Harvey R; Unsworth N; Kaur B; Savage P; Sarwar N; Seckl MJ
ESMO Open; 2021 Jun; 6(3):100110. PubMed ID: 33845362
[TBL] [Abstract][Full Text] [Related]
6. Management of drug resistant gestational trophoblastic neoplasia.
Patel SM; Desai A
J Reprod Med; 2010; 55(7-8):296-300. PubMed ID: 20795341
[TBL] [Abstract][Full Text] [Related]
7. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ
J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528
[TBL] [Abstract][Full Text] [Related]
8. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000.
McNeish IA; Strickland S; Holden L; Rustin GJ; Foskett M; Seckl MJ; Newlands ES
J Clin Oncol; 2002 Apr; 20(7):1838-44. PubMed ID: 11919242
[TBL] [Abstract][Full Text] [Related]
9. Outcome of gestational trophoblastic neoplasia: experience from a tertiary cancer centre in India.
Gulia S; Bajpai J; Gupta S; Maheshwari A; Deodhar K; Kerkar RA; Seth V; Rekhi B; Menon S
Clin Oncol (R Coll Radiol); 2014 Jan; 26(1):39-44. PubMed ID: 24051171
[TBL] [Abstract][Full Text] [Related]
10. [EMA/CO regimen for chemotherapy 24 patients with ultra high-risk gestational trophoblastic neoplasia].
Shen T; Chen LL; Qin JL; Wang XY; Cheng XD; Xie X; Lyu WG
Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):371-376. PubMed ID: 29961278
[No Abstract] [Full Text] [Related]
11. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia.
Lurain JR; Schink JC
J Reprod Med; 2012; 57(5-6):219-24. PubMed ID: 22696816
[TBL] [Abstract][Full Text] [Related]
12. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia.
Lurain JR; Nejad B
Gynecol Oncol; 2005 May; 97(2):618-23. PubMed ID: 15863169
[TBL] [Abstract][Full Text] [Related]
13. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia.
Lybol C; Thomas CM; Blanken EA; Sweep FC; Verheijen RH; Westermann AM; Boere IA; Reyners AK; Massuger LF; van Hoesel RQ; Ottevanger PB
Eur J Cancer; 2013 Mar; 49(4):860-7. PubMed ID: 23099004
[TBL] [Abstract][Full Text] [Related]
14. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.
Winter MC; Tidy JA; Hills A; Ireson J; Gillett S; Singh K; Hancock BW; Coleman RE
Gynecol Oncol; 2016 Dec; 143(3):565-570. PubMed ID: 27756557
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia.
Alazzam M; Tidy J; Osborne R; Coleman R; Hancock BW; Lawrie TA
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD008891. PubMed ID: 26760424
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia.
Alazzam M; Tidy J; Osborne R; Coleman R; Hancock BW; Lawrie TA
Cochrane Database Syst Rev; 2012 Dec; 12():CD008891. PubMed ID: 23235667
[TBL] [Abstract][Full Text] [Related]
17. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy.
Escobar PF; Lurain JR; Singh DK; Bozorgi K; Fishman DA
Gynecol Oncol; 2003 Dec; 91(3):552-7. PubMed ID: 14675675
[TBL] [Abstract][Full Text] [Related]
18. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia.
Turan T; Karacay O; Tulunay G; Boran N; Koc S; Bozok S; Kose MF
Int J Gynecol Cancer; 2006; 16(3):1432-8. PubMed ID: 16803542
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
[TBL] [Abstract][Full Text] [Related]
20. Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemoresistant Germ Cell Tumors.
Raggi D; Giannatempo P; Miceli R; Farè E; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Marongiu M; Gianni AM; Nicolai N; Salvioni R; Necchi A
Am J Clin Oncol; 2017 Feb; 40(1):60-65. PubMed ID: 25089532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
